The investigation determined that discordant vitros anti- sars-cov-2 igg results were obtained from two different patient samples when processed using vitros cov2igg reagent lot 0160 on two different vitros xt7600 integrated systems.A definitive assignable cause for the discordant reactive results could not be determined with the information provided.Based on historical quality control results, a vitros cov2igg reagent performance issue is not a likely contributor to the event as all qc fluid results were within the correct ifu interpretation region.Additionally, there is no indication of an instrument malfunction and unexpected instrument performance is not a likely contributor to the event.However, it cannot be entirely ruled out as a contributing factor as precision testing to assess instrument performance was not performed by the customer when requested.In addition, pre-analytical sample processing could not be ruled out as a contributing factor, as it was established that the customer was not following the sample collection device manufacturers recommendation for sample centrifugation and cellular debris, due to poor sample preparation, was likely present in the affected sample, although this could not be confirmed.The most likely cause of the discordant results in this case is the vitros cov2igg test generated false positive results for the samples under test.The vitros cov2igg ifu does not preclude the possibility of false positive cov2igg results due to cross-reactivity from pre-existing antibodies or other possible causes.Continual tracking and trending of complaints has not identified any signals that would point to a potential systemic issue with vitros cov2igg lot 0160.
|